Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | QDPR | P09417 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27886023 | 0.85 | MEN1 (0.71) | MEN1KMT2ACNR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5547905 | 0.83 | SIGMAR1 (0.49) | MEN1KMT2ACNR1SIGMAR1QDPR | |
| SCHEMBL4947674 | 0.81 | ALDH1A1 (0.50) | MEN1KMT2ACNR1SIGMAR1QDPR | |
| SCHEMBL1198534 | 0.81 | MEN1 (0.51) | MEN1KMT2ACNR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20414631 | 0.78 | MEN1 (0.45) | MEN1KMT2ACNR1SIGMAR1ALDH1A1 | |
| SCHEMBL2179178 | 0.78 | RAB9A (0.46) | MEN1KMT2ACNR1SIGMAR1QDPR | |
| SCHEMBL18113482 | 0.78 | MEN1 (0.43) | MEN1KMT2ACNR1QDPRTSHR | |
| SCHEMBL21158027 | 0.77 | KMT2A (0.46) | MEN1KMT2ACNR1QDPRALDH1A1 | |
| SCHEMBL19297504 | 0.77 | QDPR (0.49) | MEN1KMT2ASIGMAR1QDPRALDH1A1 | |
| SCHEMBL185625 | 0.76 | CNR1 (0.46) | MEN1KMT2ACNR1SIGMAR1QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519143-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI (FR) | 2013-08-27 | — | — | US | claimed |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-11-15 | — | — | US | claimed |
| EP-2513088-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI (FR) | 2012-10-24 | — | — | EP | claimed |
| US-20120245150-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | claimed |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2012-09-13 | — | — | US | claimed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-2297148-B8 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-03-28 | — | — | EP | claimed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | claimed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | claimed |
| WO-2011080445-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | claimed |
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2310383-A1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-20 | — | — | EP | claimed |
| EP-2297148-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | Sanofi-Aventis (FR) | 2011-03-23 | — | — | EP | claimed |
| WO-2009150387-A1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | claimed |
| WO-2009150388-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | claimed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | MEN1 2350/4885KMT2A 2396/4885CNR1 47/4885 |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MEN1 4190/4885KMT2A 4374/4885CNR1 1515/4885 |
| US-20120245150-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK1, NTRK3 | MEN1 4024/4885KMT2A 3840/4885CNR1 406/4885 |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | MEN1 4190/4885KMT2A 4374/4885CNR1 1515/4885 |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | MEN1 2350/4885KMT2A 2396/4885CNR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.